Prospective evaluation of fexapotide triflutate injection treatment of Grade Group 1 prostate cancer: 4-year results

PURPOSE: This study was undertaken to determine the safety and efficacy of fexapotide triflutate (FT) 2.5 mg and 15 mg for the treatment of Grade Group 1 prostate cancer. METHODS: Prospective randomized transrectal intraprostatic single injection FT 2.5 mg (n = 49), FT 15 mg (n = 48) and control act...

Descripción completa

Detalles Bibliográficos
Autores principales: Shore, Neal, Kaplan, Steven A., Tutrone, Ronald, Levin, Richard, Bailen, James, Hay, Alan, Kalota, Susan, Bidair, Mohamed, Freedman, Sheldon, Goldberg, Kenneth, Snoy, Frederick, Epstein, Jonathan I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7716857/
https://www.ncbi.nlm.nih.gov/pubmed/32088746
http://dx.doi.org/10.1007/s00345-020-03127-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7716857/
https://www.ncbi.nlm.nih.gov/pubmed/32088746
http://dx.doi.org/10.1007/s00345-020-03127-w

Ejemplares similares